

# Wah Kheong Chan

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6752643/wah-kheong-chan-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

87  
papers

3,411  
citations

27  
h-index

57  
g-index

108  
ext. papers

5,558  
ext. citations

5.8  
avg, IF

5.51  
L-index

#	Paper	IF	Citations
87	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 202-209	13.4	764
86	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1022-1030	13.4	415
85	Epidemiology of Helicobacter pylori infection and public health implications. <i>Helicobacter</i> , <b>2011</b> , 16 Suppl 1, 1-9	4.9	231
84	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 70-85	4	211
83	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 362-373	18.8	151
82	Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 1470-64		116
81	A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1940-1949.e8	6.9	92
80	Appointment waiting times and education level influence the quality of bowel preparation in adult patients undergoing colonoscopy. <i>BMC Gastroenterology</i> , <b>2011</b> , 11, 86	3	84
79	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 86-98 <sup>4</sup>		71
78	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , <b>2019</b> , 68, 2057-2064	19.2	65
77	Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 623-631	4	65
76	Non-alcoholic fatty liver disease in diabetics--prevalence and predictive factors in a multiracial hospital clinic population in Malaysia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2013</b> , 28, 1375-83	4	52
75	Controlled attenuation parameter using the FibroScan XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. <i>United European Gastroenterology Journal</i> , <b>2017</b> , 5, 76-85	5.3	51
74	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 776-787	18.8	51
73	Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2570-2580.e37	6.9	40
72	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> ,	24.2	37
71	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 185-198	18.8	36

70	Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1405-13	4	35
69	A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis. <i>Hepatology International</i> , <b>2015</b> , 9, 594-602	8.8	34
68	Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1396-1403	4	33
67	Epidemiology of a fast emerging disease in the Asia-Pacific region: non-alcoholic fatty liver disease. <i>Hepatology International</i> , <b>2013</b> , 7, 65-71	8.8	32
66	Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 816-825	6.1	31
65	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , <b>2021</b> ,	19.2	31
64	Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications. <i>JGH Open</i> , <b>2018</b> , 2, 235-241	1.8	30
63	Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 989-1000	6.1	28
62	Genome-wide analysis of copy number variation identifies candidate gene loci associated with the progression of non-alcoholic fatty liver disease. <i>PLoS ONE</i> , <b>2014</b> , 9, e95604	3.7	27
61	Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 1787-1794	4	26
60	Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers. <i>PLoS ONE</i> , <b>2014</b> , 9, e105903	3.7	21
59	Epidemiology of non-alcoholic fatty liver disease in Asia. <i>Indian Journal of Gastroenterology</i> , <b>2020</b> , 39, 1-8	1.9	20
58	Non-alcoholic fatty liver disease in a young multiracial Asian population: a worrying ethnic predilection in Malay and Indian males. <i>Hepatology International</i> , <b>2014</b> , 8, 121-7	8.8	19
57	Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease. <i>Hepatology International</i> , <b>2018</b> , 12, 44-55	8.8	18
56	Split-dose vs same-day reduced-volume polyethylene glycol electrolyte lavage solution for morning colonoscopy. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 14488-94	5.6	18
55	Global multi-stakeholder endorsement of the MAFLD definition.. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2022</b> ,	18.8	18
54	Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , <b>2017</b> , 12, e0174982	3.7	17
53	MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis. <i>Liver International</i> , <b>2019</b> , 39, 1315-1324	7.9	15

52	Comparing point shear wave elastography (ElastPQ) and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 135-141	4	15
51	Validation study of the Leeds Dyspepsia Questionnaire in a multi-ethnic Asian population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26, 1669-76	4	14
50	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 867-875	0.7	13
49	Endoscopic ultrasound-guided tissue acquisition with or without macroscopic on-site evaluation: randomized controlled trial. <i>Endoscopy</i> , <b>2020</b> , 52, 856-863	3.4	13
48	Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 88	3	12
47	Narrow-band imaging and white-light endoscopy with optical magnification in the diagnosis of dysplasia in Barrett's esophagus: results of the Asia-Pacific Barrett's Consortium. <i>Endoscopy International Open</i> , <b>2015</b> , 3, E14-8	3	11
46	Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2020</b> , 40, 2719-2731	7.9	11
45	Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 320-325	4	11
44	Ultrasonography-diagnosed non-alcoholic fatty liver disease is not associated with prevalent ischemic heart disease among diabetics in a multiracial Asian hospital clinic population. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2014</b> , 38, 284-91	2.4	10
43	Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study. <i>Journal of Digestive Diseases</i> , <b>2014</b> , 15, 545-52	3.3	9
42	Nonalcoholic Fatty Liver Disease: A Global Perspective. <i>Clinical Therapeutics</i> , <b>2021</b> , 43, 473-499	3.5	9
41	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	9
40	Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy. <i>Journal of Digestive Diseases</i> , <b>2015</b> , 16, 537-40	3.3	8
39	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2843-2845.e2	6.9	8
38	Epidemiological differences of common liver conditions between Asia and the West. <i>JGH Open</i> , <b>2020</b> , 4, 332-339	1.8	7
37	Association between non-alcoholic fatty liver disease evaluated by transient elastography with extracranial carotid atherosclerosis in a multiethnic Asian community. <i>JGH Open</i> , <b>2019</b> , 3, 117-125	1.8	6
36	Evaluation of patient satisfaction of an outpatient gastroscopy service in an Asian tertiary care hospital. <i>BMC Gastroenterology</i> , <b>2012</b> , 12, 96	3	6
35	Clinical outcomes and direct costings of endoluminal clipping compared to surgery in the management of iatrogenic colonic perforation. <i>Journal of Digestive Diseases</i> , <b>2013</b> , 14, 670-5	3.3	6

34	Evaluation of patient satisfaction of an outpatient colonoscopy service in an asian tertiary care hospital. <i>Gastroenterology Research and Practice</i> , <b>2012</b> , 2012, 561893	2	6
33	Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 2416-2426	5.6	6
32	Asian perspective on NAFLD-associated HCC. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	6
31	Liver stiffness measurement in non-alcoholic fatty liver disease: Two is better than one. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 1404-1411	4	6
30	Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 470-480	6.1	6
29	Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 148-156	18.8	6
28	Noninvasive Tests in the Assessment of NASH and NAFLD Fibrosis: Now and Into the Future. <i>Seminars in Liver Disease</i> , <b>2020</b> , 40, 331-338	7.3	5
27	Copy number variation in exportin-4 (XPO4) gene and its association with histological severity of non-alcoholic fatty liver disease. <i>Scientific Reports</i> , <b>2015</b> , 5, 13306	4.9	5
26	Endorsing the redefinition of fatty liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 163	18.8	5
25	Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort. <i>Clinical and Molecular Hepatology</i> , <b>2021</b> , 27, 486-498	6.9	5
24	Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 1804-1812	4	4
23	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	4
22	Diagnosis of Fibrosis Using Blood Markers and Logistic Regression in Southeast Asian Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 637652	4.9	4
21	Quantification of Liver Fat in NAFLD: Available Modalities and Clinical Significance. <i>Current Hepatology Reports</i> , <b>2019</b> , 18, 492-502	1	3
20	Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 1297-1305	3.4	3
19	Volumetric Liver Fat Fraction Determines Grade of Steatosis More Accurately Than Controlled Attenuation Parameter in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 945-953.e2	6.9	3
18	Low physical activity and energy dense Malaysian foods are associated with non-alcoholic fatty liver disease in centrally obese but not in non-centrally obese patients with diabetes mellitus. <i>Asia Pacific Journal of Clinical Nutrition</i> , <b>2015</b> , 24, 289-98	1	3
17	Limited applicability of cathepsin D for the diagnosis and monitoring of non-alcoholic steatohepatitis. <i>JGH Open</i> , <b>2019</b> , 3, 417-424	1.8	2

16	Emerging new standard for non-invasive assessment of liver disease mortality in non-alcoholic fatty liver disease. <i>Hepatobiliary Surgery and Nutrition</i> , <b>2017</b> , 6, 135-137	2.1	2
15	Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. <i>Metabolism: Clinical and Experimental</i> , <b>2022</b> , 126, 154911	12.7	2
14	Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease. <i>PLoS ONE</i> , <b>2021</b> , 16, e0250300	3.7	2
13	Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in noncirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: The STORM-C-1 phase II/III trial. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S123-S124	13.4	2
12	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. <i>EClinicalMedicine</i> , <b>2021</b> , 41, 101145	11.3	2
11	Endoscopic sleeve gastropasty: Case report, technique and literature review. <i>Journal of Digestive Diseases</i> , <b>2017</b> , 18, 598-603	3.3	1
10	Commentary: changing aetiology of peptic ulcers. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 291-2; discussion 292-3	6.1	1
9	Cyclosporine rescue therapy in autoimmune liver cirrhosis: a case report. <i>Turkish Journal of Gastroenterology</i> , <b>2012</b> , 23, 599-603	1	1
8	Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 751-757	4	1
7	Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.. <i>World Journal of Gastroenterology</i> , <b>2022</b> , 28, 1563-1573	5.6	1
6	Use of simple scoring systems for a public health approach in the management of non-alcoholic fatty liver disease patients. <i>JGH Open</i> , <b>2020</b> , 4, 1155-1161	1.8	0
5	A new bile acid treatment for non-alcoholic fatty liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 747-749	18.8	0
4	Reply to: CHAI and MACK-3 as noninvasive indices for nonalcoholic steatohepatitis. <i>Liver International</i> , <b>2019</b> , 39, 1588	7.9	
3	Allele HLA-DQB1*06 reduces fibrosis score in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , <b>2020</b> , 50, 947-954	5.1	
2	Endoscopic Management of Colonoscopy-related Perforation. <i>Journal of Digestive Endoscopy</i> , <b>2018</b> , 09, 047-052	0.4	
1	Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 2415-2425	5.6	